Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists

Documenti analoghi

• Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
  di: Darren Lau, et al.
  Pubblicazione: (2024)
• A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
  di: Filip K. Knop, et al.
  Pubblicazione: (2024)
• Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure
  di: Karen L. Jones, et al.
  Pubblicazione: (2024)
• Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
  di: Yunwen Xu, et al.
  Pubblicazione: (2025)
• Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
  di: Fu‐Shun Yen, et al.
  Pubblicazione: (2025)